Navigation Links
Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
Date:11/4/2009

iency, and a non-opioid solution designed to potentially treat chronic pain.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: the potential value of tezampanel and NGX426 in the treatment of migraine, chronic pain, and other diseases; Raptor's ability to spin out or partner the tezampanel and NGX426 pain program; Raptor's ability to ensure that its shareholders receive the maximum value from tezampanel and NGX426; that tezampanel and NGX426 can be potentially groundbreaking drugs; and Raptor's ability to successfully develop any of its product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is un
'/>"/>

SOURCE Raptor Pharmaceutical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
2. Raptor Pharmaceutical Expands Board of Directors
3. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
4. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
5. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
6. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. Raptor Pharmaceuticals Provides Update on Targeting Platforms
10. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
11. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ALTO, Calif. , July 28, 2015 ... Holding Corp., the parent company of CPI International, Inc. ... third quarter ended July 3, 2015 with the Securities ... regarding its results for the quarter.  At 11 a.m. ... a telephonic conference call in conjunction with this release ...
(Date:7/28/2015)... PARK, Calif. , July 28, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based ... announced the publication of the SENZA-RCT results in ... official Journal of the American Society of Anesthesiologists. ... a ground-breaking study that was the first to ...
(Date:7/28/2015)... 28, 2015  SeraCare Life Sciences, a leading ... today at the American Association of Clinical Chemistry ... agreement with the University of California, San Francisco ... Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast ... "patient-like" reference materials for Non-Invasive Prenatal Testing (NIPT) ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3
... Major Lupin Limited announced today that its U.S. subsidiary, ... Award by the Healthcare Distribution Management Association (HDMA) for ... with sales of up to $100 million in the ... winners are selected by HDMA Distributor members to recognize ...
... Laboratories, a leading provider of medication monitoring services to ... hiring of Martin Price as General Counsel and Janna ... Officer. As Millennium Laboratories General Counsel, Mr. ... Howard Appel , Millennium Laboratories, President, said, "We ...
Cached Medicine Technology:HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 2HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 3Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 2Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 3
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a talk on ... noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center ... is board-certified in colorectal surgery and has more than 35 years of experience in ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
(Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... targeted biologics and biologic-device combination products for the treatment of bone disorders and ... U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
Breaking Medicine News(10 mins):Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... on an enzyme that is critical to the process ... target of antibacterial and anticancer drugs. Researchers with the ... Lab) and the University of California (UC) at Berkeley ... DNA-bound Type II topoisomerase (topo II) that is responsible ...
... for Dealing With Elderly Holiday Blues Offered by One of the ... ... of the country,s senior,healthcare experts from the world-renowned Los Angeles Jewish ... group,particularly vulnerable to the blues at this time of year -- ...
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... children , , THURSDAY, Dec. 20 (HealthDay News) -- Holiday toys ... are threatening to cause more worry than joy. , Millions ... months by toy companies, many because they were decorated with ... Barbie, and Thomas the Tank Engine, among others. , The ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
Cached Medicine News:Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:First look at an enzyme target for antibacterial and cancer drugs 2Health News:First look at an enzyme target for antibacterial and cancer drugs 3Health News:First look at an enzyme target for antibacterial and cancer drugs 4Health News:It's Not Just About the Children 2Health News:It's Not Just About the Children 3Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Make Safe Toys Your Holiday Priority 2Health News:Make Safe Toys Your Holiday Priority 3Health News:Gloomy forecast for Nobel Direct after 3 years 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: